Intranasal H5 Influenza Vaccine
H5 Influenza (Avian/Bird Flu, Pandemic Preparedness)
Phase 1Active
Key Facts
Indication
H5 Influenza (Avian/Bird Flu, Pandemic Preparedness)
Phase
Phase 1
Status
Active
Company
About BlueWillow Biologics
BlueWillow Biologics is a private, clinical-stage biotechnology company pioneering intranasal vaccine development with its NanoVax® adjuvant platform. The company's technology, which originated at the University of Michigan, has demonstrated safety and immunogenicity in multiple Phase 1 human trials, including a recent H5 influenza (bird flu) study. BlueWillow aims to transform vaccine delivery and efficacy for respiratory and other mucosal pathogens by enabling needle-free, self-administered vaccines that can block infection and transmission.
View full company profile